AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-27: Cancelled.

Claim 28 (Currently amended): A process for manufacturing a pharmaceutical drug product having an active core, comprising the steps of:

A) mixing ethylcellulose, an organic solvent, and a surfactant to form a moisture barrier coating solution, wherein the ratio of the surfactant to the ethylcellulose is 1.00:0.165;

B) coating a drug substance with said coating solution to form said active core, wherein said coating solution is adapted to allowing ~~normal~~ immediate release of said drug substance in a gastro-intestinal environment of a mammal;

C) forming a unit dosage form from said active core~~, wherein said unit dosage form optionally comprises one or more pharmaceutically acceptable excipients~~.

Claim 29 (Previously presented): The process of claim 49, wherein said outer layer comprises a gelatin capsule.

Claim 30 (Currrently amended): The process of claim 28, wherein said surfactant comprises polysorbate 80~~, and wherein said polysorbate 80 and said ethylcellulose are present in a ratio of approximately 1.00 : 0.165~~.

Claim 31 (Original): The process of claim 28, wherein said drug substance comprises paroxetine.

Claim 32 (Original): The process of claim 28, wherein said surfactant comprises polysorbate 80, and wherein said polysorbate 80 and said ethylcellulose are present in a ratio of approximately 1.00 : 0.165, and wherein said drug substance comprises paroxetine.

Claim 33 (Currently amended): A substantially moisture stable pharmaceutical drug product comprising:

paroxetine or a pharmaceutically acceptable salt thereof; ethylcellulose; and a surfactant, wherein the ratio of the surfactant to the ethylcellulose is 1.00:0.165, and wherein the ethylcellulose and surfactant forming a coating for said paroxetine that is adapted to retarding degradation of said paroxetine while allowing ~~normal~~ immediate release of said paroxetine in a gastro-intestinal environment of a mammal.

Claim 34 (Currently amended): The drug product of claim 33, wherein

said surfactant comprises polysorbate 80~~, and wherein said polysorbate 80 and said ethylcellulose are present in a ratio of approximately 1.00 : 1.65~~.

Claim 35 (Previously presented): The drug product of claim 33, further comprising an outer layer surrounding said core, wherein said outer layer comprises pharmaceutically acceptable excipients and is substantially free of said paroxetine.

Claim 36 (Cancelled)

Claim 37 (Previously presented): The drug product of claim 33, wherein said paroxetine comprises granules comprising paroxetine or a pharmaceutically acceptable salt thereof and wherein said coating optionally penetrates said paroxetine granules.

Claim 38 (Previously presented): The drug product of claim 37, wherein said surfactant comprises polysorbate 80.

Claim 39 (Previously presented): The drug product of claim 36, wherein said surfactant comprises polysorbate 80.

Claim 40 (Previously presented): The drug product of claim 35, wherein said paroxetine, coating, and outer layer form a unit dosage form of said drug product.

Claim 41 (Previously presented): The drug product of claim 40, wherein said unit dosage form is a tablet.

Claim 42 (Previously presented): The drug product of claim 41, wherein said tablet is optionally seal coated with one or more hydrophobic excipient.

Claim 43 (Previously presented): The drug product of claim 40, wherein said drug product is incorporated into a gelatin capsule.

Claim 44 (Currently amended): A substantially moisture stable pharmaceutical drug product comprising:

a substantially moisture stable active core comprising a drug substance coated with ethyl cellulose and a surfactant, wherein the ratio of the surfactant to the ethylcellulose is 1.00:0.165, and wherein said coating is adapted to allowing ~~normal~~ immediate release of said drug substance in a gastro-intestinal environment of a mammal; and

an outer layer surrounding said active core, wherein ~~said outer layer comprising one or more pharmaceutically acceptable excipients and wherein~~ said outer layer is substantially free of said drug substance.

Claim 45 (Previously presented): The drug product of claim 44, wherein the outer layer comprises an inactive gelatin capsule.

Claim 46 (Previously presented): The drug product of claim 44, wherein said drug substance is paroxetine hydrochloride.

Claim 47 (Previously presented): The drug product of claim 44, wherein the surfactant is polysorbate 80.

Claim 48 (cancelled)

Claim 49 (Previously presented): The process of claim 28, further comprising the step of forming an outer layer surrounding said active core, wherein said outer layer comprising one or more pharmaceutically acceptable excipients and wherein said outer layer is substantially free of said drug substance.

Claim 50 (Previously presented): The process of claim 28, further comprising the step of:

D) combining said coated drug substance and said one or more pharmaceutically acceptable excipents; and

E) granulating the combination formed in step D),

wherein the step of forming a unit dosage form comprises using compression to form a tablet.

Claim 51 (Previously presented): The process of claim 28, further comprising the step of:

D) combining said coated drug substance and said one or more pharmaceutically acceptable excipents; and

E) granulating said combination formed in step D),

wherein the step of forming a unit dosage form comprises incorporating said granulated combination into a hard gelatin capsule.